Navigation Links
Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121
Date:11/20/2012

PARAMUS, N.J., Nov. 20, 2012 /PRNewswire/ -- PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121.

Michael Cohen, the Chief Executive Officer of the Company stated: "At least thirty (30) patients have been screened so far pursuant to inclusion and exclusion criteria approved by the Institutional Review Board as part of the protocol.  The initiation of screening is the first step towards commencement of the clinical trial of UMK-121."

About Proteonomix, Inc.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at www.proteonomix.com and www.proteoderm.com.

Forward-looking statements:

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.


'/>"/>
SOURCE Proteonomix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease
2. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
3. NeuroDerm Announces Enrollment in a Phase 1 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
4. ShangPharma Announces Third Quarter 2012 Results
5. Dr. TATTOFF Announces Use of Astanza Laser Tattoo Removal Systems for New Phoenix Location
6. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
7. Sensus Healthcare Announces Health Canada Approval
8. Neusoft Medical Systems, USA Announces Alignment with Landauer Medical Physics
9. Grupo Casa Saba Reports - Grupo Casa Saba Announces its Intention to Delist From the New York Stock Exchange
10. Landauer Medical Physics Announces Alignment With Neusoft Medical Systems, USA
11. The Michael J. Fox Foundation Announces Fourth Quarter Participants in Partnering Program Between Awardees and Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Inivata, a global clinical ... tumour DNA (ctDNA) analysis to improve personalised healthcare ... Clive Morris as Chief Medical Officer. ... development programme, scientific collaborations, and through to commercialisation ... in clinical outcomes for patients. Clive ...
(Date:5/24/2016)... --   , Study met ... cleansing and superiority in , Excellent ... of the ascending colon   , ... Norgine B.V. today announced new positive data from the phase III ... versus standard 2 litre PEG with ascorbate. The study met both ...
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior ... executive officer, today. In his new role, Marziani will lead the company,s business development ... professionals to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... With a ... medical and food industries. Aside from its GMP accreditation, Validation Center is also ... successfully certified products, services and staff. , Validation Center is ISO17025 accredited and ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research ... their dogs straight off the grill. Of the 90 percent of Americans who say ... a hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University College of ... programs. , Answering to the increasing demand for curricular specializations, the Certificate in ... environmental and land use law. ,  , “The demand for lawyers with specific ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card ... the country. The nonprofit Hope For Heroes partnered with the leading provider of ... disabled military veterans, as well as police, firemen, and EMS professionals across the country, ...
Breaking Medicine News(10 mins):